Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SRN-001
- Development stage
- Phase 1
- Lead developer
- siRNAgen Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
SRN-001 is a novel small interfering RNA (siRNA) therapeutic developed by siRNAgen Therapeutics for the treatment of fibrosis, particularly idiopathic pulmonary fibrosis (IPF). It utilizes Self Assembled Micelle inhibitory ribonucleic acid (SAMiRNA™) technology to deliver siRNA targeting amphiregulin (AREG), a growth factor implicated in fibroblast proliferation and myofibroblast transformation—key processes in fibrotic diseases. By downregulating AREG expression via RNA interference, SRN-001 aims to inhibit the fibroblast-to-myofibroblast transition driven by transforming growth factor-beta (TGF-β). The drug has completed Phase 1a clinical trials assessing safety, tolerability, and pharmacokinetics in healthy volunteers. No significant safety issues or immunogenicity concerns were observed at any dose level tested intravenously. The platform may have broader applicability for other fibrotic and metabolic diseases[1][2][4][5][6][7][8].
- Other names
- AmphisiranSAMiRNA-AREG
02
Targets
AREG (Amphiregulin)
Beyond the preview
Go deeper on SRN-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SRN-001.